Scutellarin inhibits high glucose-induced and hypoxia-mimetic agent-induced angiogenic effects in human retinal endothelial cells through reactive oxygen species/hypoxia-inducible factor-1a/vascular endothelial growth factor pathway

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 3, 2014, Pages 218-227

  Wang, Difei ^a   Wang, Lei ^a   Gu, Jianqiu ^a   Yang, Huijing ^a   Liu, Nanqi ^a   Lin, Yichen ^a   Li, Xiaolin ^a   Shao, Chen ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Diabetic retinopathy; Human retinal endothelial cells; Scutellarin

Indexed keywords

COBALT CHLORIDE; E1A ASSOCIATED P300 PROTEIN; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; REACTIVE OXYGEN METABOLITE; REAGENT; SCUTELLARIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; APIGENIN; COBALT; GLUCURONIC ACID; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOCHEMICAL ANALYSIS; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGRADATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOPRECIPITATION; LIPID PEROXIDATION ASSAY; LUCIFERASE ASSAY; MIGRATION; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; UBIQUITINATION; WESTERN BLOTTING; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM;

ANGIOGENESIS INHIBITORS; APIGENIN; CELL PROLIFERATION; CELLS, CULTURED; COBALT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GLUCOSE; GLUCURONATES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924856463     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000109     Document Type: Article

References (43)

1. Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013; 7: 4-10.
2. Costa PZ, Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci. 2013; 92: 1037-1045.
3. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997; 13: 37-50.
4. Thangarajah H, Yao D, Chang EI, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009; 106: 13505-13510.
5. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997; 272: 22642-22647.
6. Bento CF, Pereira P. Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia. 2011; 54: 1946-1956.
7. Meng D, Mei A, Liu J, et al. NADPH oxidase 4 mediates insulinstimulated HIF-1a and VEGF expression, and angiogenesis in vitro. PLoS One. 2012; 7: e48393.
8. Kowluru RA, Abbas SN. Diabetes-induced mitochondrial dysfunction in the retina. Invest Ophthalmol Vis Sci. 2003; 44: 5327-5334.
9. Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina retinal cells. Free Radic Biol Med. 2003; 35: 1491-1499.
10. Cui Y, Xu X, Bi H, et al. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res. 2006; 83: 807-816.
11. Ellis EA, Guberski DL, Somogyi-Mann M, et al. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/ WOR diabetic rat. Free Radic Biol Med. 2000; 28: 91-101.
12. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol. 2001; 38: 179-185.
13. Kowluru RA, Koppolu P. Termination of experimental galactosemia in rats, and progression of retinal metabolic abnormalities. Invest Ophthalmol Vis Sci. 2002; 43: 3287-3291.
14. Gao R, Zhu BH, Tang SB, et al. Scutellarein inhibits hypoxiaand moderately-high glucose-induced proliferation and VEGF expression in human retinal endothelial cells. Acta Pharmacol Sin. 2008; 29: 707-712.
15. Guo H, Hu LM, Wang SX, et al. Neuroprotective effects of scutellarin against hypoxic-ischemic-induced cerebral injury via augmentation of antioxidant defense capacity. Chin J Physiol. 2011; 54: 399-405.
16. Xu W, Zha RP, Wang WY, et al. Effects of scutellarin on PKCg in PC12 cell injury induced by oxygen and glucose deprivation. Acta Pharmacol Sin. 2007; 28: 1573-1579.
17. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms and endothelial cell growth. J Clin Invest. 1996; 98: 2018-2026.
18. Zhang Q, Li Q, Chen Y, et al. Homocysteine-impaired angiogenesis is associated with VEGF/VEGFR inhibition. Front Biosci (Elite Ed). 2012; 4: 2525-2535.
19. Julia VB, Susanne M, Maria BG. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes. 2008; 57: 1952-1965.
20. Chen WL, Qian Y, Meng WF, et al. A novel marine compound xyloketal B protects against oxidized LDL-induced cell injury in vitro. Biochem Pharmacol. 2009; 78: 941-950.
21. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16: 4604-4613.
22. NakayamaM, Nakayama A, van LessenM, et al. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol. 2013; 15: 249-260.
23. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292: 468-472.
24. Lando D, Gorman JJ, Whitelaw ML, et al. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem. 2003; 270: 781-790.
25. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16: 1466-1471.
26. Calvani M, Comito G, Giannoni E, et al. Time-dependent stabilization of hypoxia inducible factor-1a by different intracellular sources of reactive oxygen species. PLoS One. 2012; 7: e38388.
27. Gorin Y, Block K. Nox as a target for diabetic complications. Clin Sci (Lond). 2013; 125: 361-382.
28. Biswas S, Gupta MK, Chattopadhyay D, et al. Insulin-induced activation of hypoxia-inducible factor-1 requires generation of reactive oxygen species by NADPH oxidase. Am J Physiol Heart Circ Physiol. 2007; 292: H758-H766.
29. Premanand C, Rema M, Sameer MZ, et al. Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions. Invest Ophthalmol Vis Sci. 2006; 47: 2179-2184.
30. Yamamoto Y, Fujita M, Tanaka Y, et al. Low oxygen tension enhances proliferation and maintains stemness of adipose tissue-derived stromal cells. Biores Open Access. 2013; 2: 199-205.
31. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11: 174-183.
32. Gao ZX, Huang DY, Li HX, et al. Scutellarin promotes in vitro angiogenesis in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2010; 400: 151-156.
33. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995; 1: 1024-1028.
34. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292: 464-468.
35. Calvani M, Comito G, Giannoni E, et al. Time-dependent stabilization of hypoxia inducible factor-1a by different intracellular sources of reactive oxygen species. PLoS One. 2012; 7: e38388.
36. Wilkinson-Berka JL, Rana I, Armani R, et al. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond). 2013; 124: 597-615.
37. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54: 1615-1625.
38. Li SY, Fu ZJ, Lo AC. Hypoxia-induced oxidative stress in ischemic retinopathy. Oxid Med Cell Longev. 2012; 2012: 426769.
39. Datla SR, Peshavariya H, Dusting GJ, et al. Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol. 2007; 27: 2319-2324.
40. Schröder K, Zhang M, Benkhoff S, et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res. 2012; 110: 1217-1225.
41. Ribeiro JA, Messias A, Jorge R. Antiangiogenic drugs and advanced proliferative diabetic retinopathy. Arq Bras Oftalmol. 2011; 74: 143-146.
42. Han XX, Guo CM, Li Y, et al. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1a. Mol Vis. 2012; 18: 1-9.
43. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res. 2006; 83: 473-483.